Wellie Adlaon
Internal Medicine · Tishomingo, OKNPI 1245326925
Payments from drug & device makers
Across 557 payments — averaging $12.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$1K
- Johnson & Johnson$856
- Lundbeck LLC$782
- Teva Pharmaceuticals USA, Inc.$623
- Vanda Pharmaceuticals Inc.$539
- plus $2K from 12 others
What the payments were for
- Food & beverage$7,093100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 119 | $1,573 |
| AbbVie(2 entities) | 102 | $1,025 |
| Johnson & Johnson | 70 | $856 |
| Lundbeck LLC | 38 | $782 |
| Teva Pharmaceuticals USA, Inc. | 42 | $623 |
| Vanda Pharmaceuticals Inc. | 33 | $539 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $412 |
| Indivior Inc. | 32 | $391 |
| Sunovion Pharmaceuticals Inc. | 38 | $368 |
| Alkermes, Inc. | 11 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $93 |
| Neurocrine Biosciences, Inc. | 5 | $83 |
| Lilly USA, LLC | 4 | $56 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Harmony Biosciences LLC | 1 | $16 |
| Pfizer | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
How this compares
$7,093 in reported general payments places this provider in the 85th percentile of 840 internal medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PerserisRisperidone | 19 | $54,060 |
| OzempicSemaglutide | 18 | $17,513 |
| JardianceEmpagliflozin | 13 | $8,905 |
| EliquisApixaban | 12 | $7,586 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,762 |
| Lurasidone Hcl | 19 | $3,458 |
| Fluphenazine Hcl | 14 | $1,880 |
| Aripiprazole | 48 | $1,328 |
| Haloperidol | 26 | $1,149 |
| Gabapentin | 81 | $917 |
| Ziprasidone Hcl | 26 | $848 |
| Ventolin HfaAlbuterol Sulfate | 14 | $830 |
| Olanzapine | 45 | $795 |
| Clozapine | 20 | $750 |
| Benztropine Mesylate | 61 | $591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Perseris | $391 | $54,06019 claims |
| PfizerEliquis | $15 | $7,58612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $93 | $6,76214 claims |
| Lilly USA, LLCOlanzapine | $56 | $79545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Tishomingo
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Elise WiesnerNorman$584K
- Steve EgwuonwuLawton$464K
- Mousumi SomTulsa$391K
- Jesse RichardsTulsa$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.